Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp (TNXP) is a clinical-stage biopharmaceutical company developing innovative therapeutics for central nervous system disorders, immunology, and infectious diseases. This page provides timely updates on TNXP's clinical trials, regulatory milestones, and strategic initiatives.
Key resources for investors include press releases covering product development progress, partnership announcements, and financial reports. Our curated news collection helps track TNXP's pipeline candidates like TNX-102 SL for fibromyalgia and Tonmya™ for PTSD management.
Stay informed about developments in migraine therapeutics, rare disease research, and vaccine programs. Content categories include FDA communications, clinical trial results, intellectual property updates, and market expansion activities.
Bookmark this page for direct access to verified TNXP updates. Check regularly for new developments in biopharmaceutical innovation impacting patient care and treatment paradigms.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced its participation in the A.G.P. Biotech Conference, scheduled for November 30 - December 1, 2022. The conference will be virtual, allowing management to engage in investor meetings. Interested investors can arrange meetings via the conference coordinator. Tonix focuses on developing therapeutics for CNS disorders, rare diseases, immunology, and infectious diseases. Key products under development include TNX-102 SL for fibromyalgia and TNX-1300 for cocaine intoxication. Upcoming studies include Phase 2 trials for various treatments in 2023.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will present at the World Vaccine and Immunotherapy Congress 2022 in San Diego from November 28 to December 1, 2022. The presentation, titled ‘Showcase 1: Early Development of Smallpox & Monkey Pox Vaccines,’ is scheduled for December 1 at 10:40 a.m. PT. Tonix focuses on developing therapeutics for various diseases, with key candidates in CNS disorders, rare diseases, and infectious diseases. Future studies for multiple product candidates are anticipated in 2023.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) presented data on oxytocin's effects on isolated human sensory neurons at Neuroscience 2022. This study indicates oxytocin's potential role in pain modulation, citing evidence that it may serve as a non-opioid analgesic. The company anticipates starting a Phase 2 study of intranasal oxytocin for chronic migraine by 2022's end. Prior findings showed oxytocin receptors on sensory neurons, with inflammation increasing receptor presence. Additionally, magnesium significantly enhances oxytocin's analgesic effects, supporting its therapeutic use.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a poster presentation at the Neuroscience 2022 conference, scheduled for November 12-16, 2022, in San Diego. The presentation, titled “In Vitro Impact of Oxytocin on Human Sensory Neurons”, will occur on November 14, 2022, from 1:00 p.m. to 2:00 p.m. PT. Notable authors include Dr. David C. Yeomans from Stanford University and Tonix's Dr. David Hsu. The company continues to develop therapeutics for various conditions, with ongoing studies for fibromyalgia and Long COVID, while maintaining a focus on CNS, rare diseases, and immunology.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) reported third-quarter financial results for 2022, revealing cash and equivalents of $140 million. The company is advancing its pipeline, with a Phase 3 study for TNX-102 SL in fibromyalgia underway, and a Phase 2 study for Long COVID expected to show interim data in Q2 2023. R&D expenses rose to $22.2 million, driven by increased clinical activities, leading to a net loss of $29 million, or $0.69 per share. Tonix's diverse pipeline targets CNS disorders, rare diseases, and infectious diseases, with several trials anticipated to start soon.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that COO Jessica Morris will present at BioFuture on November 8, 2022, at 11:00 a.m. ET, at the Lotte New York Palace. During the event, she will host investor meetings. Interested investors can register for meetings via the BioFuture website. Tonix is focused on developing therapeutics for CNS, rare diseases, immunology, and infectious diseases, with key candidates in advanced stages, including TNX-102 SL for fibromyalgia and TNX-1300 for cocaine intoxication.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has entered a securities purchase agreement with institutional investors for 1,400,000 shares of Series A convertible redeemable preferred stock and 100,000 shares of Series B preferred stock at a price of $9.50 per share. This pricing reflects a 5% discount to the stated value of $10.00. The total gross proceeds from this offering are expected to be $15 million. The closing is anticipated on or about October 26, 2022, subject to customary conditions.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that Jessica Morris, COO, will present at the ThinkEquity Conference on October 26, 2022, at 10:30 a.m. ET in New York City. Investors can arrange meetings with the company's management via the conference coordinator. A webcast will be available on Tonix's website. Tonix focuses on developing therapeutics for various diseases including fibromyalgia and Long COVID, with several product candidates in different stages of clinical development. Key upcoming studies are expected in 2023 for multiple candidates, including TNX-1300 and TNX-601 ER.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will hold one-on-one meetings at the BIO-Europe Conference in Leipzig, Germany, from October 24-26, 2022. The conference presentation will be available to registered participants. Tonix focuses on developing therapeutics for CNS, rare diseases, immunology, and infectious diseases. Their lead candidate, TNX-102 SL, is in mid-Phase 3 trials for fibromyalgia and also targets Long COVID. Upcoming studies include TNX-1300 for cocaine intoxication and TNX-601 ER for major depressive disorder.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced FDA clearance for its IND application for TNX-601 ER, an extended-release tablet for major depressive disorder (MDD). The Phase 2 clinical trial is set to begin in Q1 2023, evaluating the efficacy and safety of the once-daily formulation. Tianeptine, already available in other countries for over 30 years, offers a unique mechanism of action distinct from traditional antidepressants, potentially exhibiting fewer side effects. TNX-601 ER also incorporates abuse-deterrent properties, aimed at minimizing misuse risks associated with tianeptine.
